Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Authors:
- Brian C. ShafferBSBrian C. Shaffer
- Kwang Woo AhnKAKwang Woo Ahn
- Zhen-Huan HuZHZhen-Huan Hu
- Taiga NishihoriTNTaiga Nishihori
- Adriana K. MaloneAMAdriana K. Malone
- David ValcárcelDVDavid Valcárcel
- Michael R. GrunwaldMGMichael R. Grunwald
- Ulrike BacherUBUlrike Bacher
- Betty HamiltonBHBetty Hamilton
- Mohamed A. Kharfan-DabajaMKMohamed A. Kharfan-Dabaja
- Ayman SaadASAyman Saad
- Corey CutlerCCCorey Cutler
- 1 June 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (16) , 1864-1871
Abstract
Purpose: To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods: We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results: Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 109/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort. Conclusion: The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.Keywords
This publication has 28 references indexed in Scilit:
- Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialHaematologica, 2010
- Hematopoietic Stem Cell Transplantation for MDSHematology/Oncology Clinics of North America, 2010
- Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex KaryotypeJournal of Clinical Oncology, 2008
- The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant ResearchBone Marrow Transplantation, 2008
- Concordance probability and discriminatory power in proportional hazards regressionBiometrika, 2005
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomeBlood, 2004
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcomeBone Marrow Transplantation, 1998
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982